Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology...

por Salas, Clara, Martín-López, Javier, Martínez-Pozo, Antonio, Hernández-Iglesias, Teresa, Carcedo, David, Ruiz de Alda, Lucia, García, J Francisco, Rojo, Federico
Publicado 2022

Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

por Nadal, Ernest, Bautista, Dolores, Cabezón-Gutiérrez, Luis, Ortega, Ana Laura, Torres, Héctor, Carcedo, David, Ruiz de Alda, Lucía, Garcia, J. Francisco, Vieitez, Paula, Rojo, Federico
Publicado 2021

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

por Majem, Margarita, Álvarez, Rosa, Ortega, Ana Laura, Ruiz de Alda, Lucía, Gordo, Rocío, García, J Francisco, Ivanova-Markova, Yoana, González-Domínguez, Almudena, San Cristóbal, Raquel Sánchez, Rojo, Federico
Publicado 2022